---
figid: PMC6932950__fcell-07-00335-g001
figtitle: An overview of current and emerging agents for TNBC therapy
organisms:
- Homo sapiens
pmcid: PMC6932950
filename: fcell-07-00335-g001.jpg
figlink: /pmc/articles/PMC6932950/figure/F1/
number: F1
caption: An overview of current and emerging agents for TNBC therapy. (A) TNBC therapies
  targeting the cell surface and cytoplasm. Cell surface therapies include inhibitors
  of immune tolerance inducing proteins such as PD1 and PD-L1. Cytoplasmic therapies
  include inhibitors of the Ras/MAPK pathway, especially MEK inhibitors, inhibitors
  of the PI3K/AKT/mTOR pathway, inhibitors of the Hedgehog signaling pathway, and
  cell cycle inhibitors such as paclitaxel and CDK inhibitors. (B) TNBC therapies
  targeting the nucleus. These therapies tend to target DNA synthesis and repair pathways
  or affect DNA viability to induce cell-cycle arrest and cell death.
papertitle: Therapeutic and Mechanistic Perspectives of Protein Complexes in Breast
  Cancer.
reftext: Mark P. Waterhouse, et al. Front Cell Dev Biol. 2019;7:335.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9156718
figid_alias: PMC6932950__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6932950__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6932950__fcell-07-00335-g001.html
  '@type': Dataset
  description: An overview of current and emerging agents for TNBC therapy. (A) TNBC
    therapies targeting the cell surface and cytoplasm. Cell surface therapies include
    inhibitors of immune tolerance inducing proteins such as PD1 and PD-L1. Cytoplasmic
    therapies include inhibitors of the Ras/MAPK pathway, especially MEK inhibitors,
    inhibitors of the PI3K/AKT/mTOR pathway, inhibitors of the Hedgehog signaling
    pathway, and cell cycle inhibitors such as paclitaxel and CDK inhibitors. (B)
    TNBC therapies targeting the nucleus. These therapies tend to target DNA synthesis
    and repair pathways or affect DNA viability to induce cell-cycle arrest and cell
    death.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - SHH
  - MTOR
  - KRAS
  - HRAS
  - NRAS
  - PTCH1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - DHH
  - IHH
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - CDK4
  - SMO
  - SMOX
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CD274
  - DHFR
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - MMUT
  - BRCA1
  - paclitaxel
  - Thymidine
  - mitoxantrone
  - doxorubicin
  - cyclophosphamide
  - cisplatin
---
